POZ April/May 2024
POZ April/May 2024
In every issue of POZ, you’ll find the latest health news, personal stories and much more.
Also Available On:
Features
Reflecting on 30 Years of POZ
A look back at three decades of HIV coverage
30 Leaders Look to the Future of HIV
As POZ marks 30 years of service, we reflect on what’s next.
Editor’s Letter
The Best Is Yet to Come
As POZ commemorates 30 years of service, we take a look at where we’ve been and where the HIV community is going.
POZ Q & A
Free and Grateful
Formerly incarcerated, Kerry Thomas takes on a new role at the Sero Project to fight HIV criminalization.
POZ Planet
Man Dies After Alleged Denial of HIV Meds
Lawsuit claims he didn’t receive treatment for two months.
R.I.P. “Feisty Fighter” Frankie Franklin-Foxx
In 1988, she was a founding member of the Chicago Women’s AIDS Project.
Fighting HIV Among Homeless People
A Boston program suppressed viral load and lowered new HIV cases.
Less Than 1% of ER Visits Include HIV Testing
Emergency rooms can offer access to HIV services.
Changing Laws and Changing Lives
Advocate Lashanda Salinas helped reform Tennessee’s HIV criminalization laws.
Everyday – April/May 2024
These dates represent milestones in the HIV epidemic. Visit poz.com/aidsiseveryday to learn more about the history of HIV and AIDS.
Voices
Stay Strong
NMAC executive director acknowledges that efforts to reduce HIV funding were beat back in 2023 but cautions against complacency in 2024.
Care & Treatment
Early HIV Treatment Boosts Immune Recovery
While there was once uncertainty about when to start antiretrovirals, it is now well established that sooner is better.
Exercise Reduces Belly and Liver Fat
Weight gain is a growing concern for HIV-positive people.
HIV Risk Factors Among Transgender Women
The findings come from the National HIV Behavioral Surveillance Among Transgender Women project, which surveyed more than 1,600 participants
Changing Causes of Death Among People With HIV
One recent analysis looked at mortality trends among more than 189,000 adults in North America and Europe.
Basics
Human Papillomavirus
Some types of HPV can cause cervical, anal and other types of cancer.
Research Notes
Prevention: Lenacapavir PrEP
If found to be effective, lenacapavir could become the longest-acting PrEP option, administered just once every six months.
Treatment: Dolutegravir Resistance
Dolutegravir is a recommended first-line option in U.S. treatment guidelines and one of the most widely used HIV medications worldwide.
Cure: Cure for Babies?
Findings from a study suggest that starting antiretrovirals within the first days of life may lead to sustained viral control.
Concerns: Too Many Meds
Findings suggest that regular reviews can help ensure that older people are not taking meds that are unnecessary or inappropriate.
POZ Hero
Englishman in New Jersey
Peter Oates began working as an AIDS nurse in 1994, the same year he tested positive for HIV.
Survey
The Cost of Care
Take our survey about your health care coverage and costs.
Digital Edition
POZ April/May 2024
Read the digital edition of this issue!
